We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+16.36%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.64B
AUM Growth
+$102M
Cap. Flow
-$45.8M
Cap. Flow %
-2.79%
Top 10 Hldgs %
45.39%
Holding
76
New
16
Increased
22
Reduced
20
Closed
12

Top Buys

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$54.8M
2
CNC icon
Centene
CNC
+$30.1M
3
ARRY
Array Biopharma Inc
ARRY
+$27.2M
4
EW icon
Edwards Lifesciences
EW
+$23.9M
5
ELGX
Endologix Inc
ELGX
+$21.5M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$48.4M
2
INCY icon
Incyte
INCY
+$41.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$29.9M
4
IMMU
Immunomedics Inc
IMMU
+$21.9M
5
PTHN
Patheon N.V.
PTHN
+$21.8M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Financials 1.4%
3 Communication Services 0.69%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
51
Fate Therapeutics
FATE
$294M
$4.6M 0.28%
1,419,058
– –
OVID icon
52
Ovid Therapeutics
OVID
$442M
$4.24M 0.26%
+448,781
New +$5.86M
ACRS icon
53
Aclaris Therapeutics
ACRS
$761M
$2.56M 0.16%
94,560
+3,860
+4% +$105K
AUPH icon
54
Aurinia Pharmaceuticals
AUPH
$1.96B
$2.04M 0.12%
332,310
+192,067
+137% +$1.29M
UNH icon
55
UnitedHealth
UNH
$385B
$337K 0.02%
1,820
– –
NBIX icon
56
Neurocrine Biosciences
NBIX
$17.6B
$305K 0.02%
6,640
-615,705
-99% -$29.9M
AGN
57
DELISTED
Allergan plc
AGN
$292K 0.02%
+1,200
New +$282K
NKTR icon
58
Nektar Therapeutics
NKTR
$2.32B
$285K 0.02%
+972
New +$281K
INSM icon
59
Insmed
INSM
$23.2B
$212K 0.01%
+12,380
New +$211K
AMED
60
DELISTED
Amedisys
AMED
$211K 0.01%
3,356
-1,470
-30% -$85.6K
BKD icon
61
Brookdale Senior Living
BKD
$3.46B
$178K 0.01%
+12,110
New +$167K
ADVM
62
DELISTED
Adverum Biotechnologies
ADVM
$56K ﹤0.01%
2,224
– –
CSLT
63
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$42K ﹤0.01%
10,229
– –
CRL icon
64
Charles River Laboratories
CRL
$10.9B
– –
-121,307
Closed -$10.9M
DVAX
65
DELISTED
Dynavax Technologies
DVAX
– –
-1,019,491
Closed -$6.07M
INCY icon
66
Incyte
INCY
$23.3B
– –
-307,723
Closed -$41.1M
MCK icon
67
McKesson
MCK
$96.2B
– –
-78,300
Closed -$11.6M
SGRY icon
68
Surgery Partners
SGRY
$1.99B
– –
-303,500
Closed -$5.92M
IMMU
69
DELISTED
Immunomedics Inc
IMMU
– –
-3,380,846
Closed -$21.9M
RARX
70
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-110,769
Closed -$2.36M
DPLO
71
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
– –
-1,254,342
Closed -$20M
ESRX
72
DELISTED
Express Scripts Holding Company
ESRX
– –
-293,807
Closed -$19.4M
AVXS
73
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-45,349
Closed -$3.45M
PRXL
74
DELISTED
Parexel International Corp
PRXL
– –
-260,231
Closed -$16.4M
PTHN
75
DELISTED
Patheon N.V.
PTHN
– –
-826,843
Closed -$21.8M
1 2
3

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q2 2017 Portfolio in Review

As of Q2 2017, Redmile Group held 76 positions worth $1.64B, up 6.6% from $1.54B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Redmile Group's Q2 2017 filing shows 16 new, 22 increased, 20 reduced and 12 closed positions. Its largest new stake was Juno Therapeutics, Inc.: 2,219,616 shares worth $66.3M. The largest sale was Puma Biotechnology, an estimated $48.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Financials and Communication Services.

  • Redmile Group's largest Q2 2017 buy was Juno Therapeutics, Inc.: 2,219,616 shares worth $66.3M.
  • Redmile Group added most to Array Biopharma Inc in Q2 2017, an estimated $27.2M increase.
  • Redmile Group's biggest Q2 2017 reduction was Puma Biotechnology, cutting an estimated $48.4M.
  • Redmile Group fully exited Incyte in Q2 2017, selling an estimated $41.1M.
  • Redmile Group's ten largest holdings make up 45% of its $1.64B portfolio in Q2 2017.
  • Redmile Group opened 16 new positions and closed 12 in Q2 2017.
  • Redmile Group's portfolio value rose 6.6% quarter-over-quarter to $1.64B.

Based on Redmile Group's 13F filing for Q2 2017, filed 15 Aug 2017.